Novartis History & Founding Timeline

Novartis acquired Alcon, the ophthalmology device and surgical company, for $52 billion in 2011 but took eight years to separate it — during which time the business underperformed and consumed management attention. The delayed spin-off of Alcon in 2019 was widely viewed as a lesson in the cost of holding non-core assets too long.

The 2019 pricing of Zolgensma (gene therapy for spinal muscular atrophy) at $2.1 million per dose — the most expensive drug in history at the time — generated intense public and political backlash. While the price reflected genuine clinical value, the communication strategy was perceived as tone-deaf, contributing to broader pharmaceutical pricing reform pressure.

Despite being first to market with CAR-T therapy, Kymriah's commercial performance has consistently disappointed relative to initial expectations due to manufacturing complexity, patient eligibility constraints, and competitive pressure from Gilead's Yescarta. The launch highlighted the gap between scientific innovation and commercial execution in cell therapy.

The sale of the Novartis Consumer Health joint venture (with GSK) in the early 2010s left the company without a stable, lower-volatility revenue stream that has since proven valuable to peers during pipeline transitions. While strategically logical, the timing left Novartis more exposed to the patent cliff on Gleevec and Diovan than it might otherwise have been.